KLP Kapitalforvaltning AS Has $12.88 Million Stock Position in Insmed, Inc. $INSM

Key Points

• KLP Kapitalforvaltning AS boosted its stake in Insmed by 80.5% in Q4 to 74,000 shares, valued at about $12.88 million.
• Corporate insiders have been net sellers — insiders sold 179,777 shares worth roughly $28.25 million over the past 90 days, including CEO William Lewis (~$1.54M) and COO Roger Adsett (~$14.5M), leaving insiders with 2.10% ownership.
• Analysts are broadly positive with an average rating of "Buy" and an average target of $213.23, but Insmed recently missed quarterly EPS (reported -$1.54 vs. est. -$1.07) and continues to show deeply negative margins.

KLP Kapitalforvaltning AS boosted its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 80.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 74,000 shares of the biopharmaceutical company's stock after purchasing an additional 33,000 shares during the period. KLP Kapitalforvaltning AS's holdings in Insmed were worth $12,879,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. CIBC Private Wealth Group LLC lifted its stake in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 53 shares during the last quarter. CoreCap Advisors LLC acquired a new stake in Insmed in the 4th quarter valued at about $27,000. Stone House Investment Management LLC acquired a new stake in Insmed in the 3rd quarter valued at about $29,000. SBI Securities Co. Ltd. lifted its stake in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 166 shares during the last quarter. Finally, GraniteShares Advisors LLC acquired a new stake in Insmed in the 4th quarter valued at about $30,000.

Analyst Upgrades and Downgrades

INSM has been the subject of several research reports. Royal Bank Of Canada raised their price objective on shares of Insmed from $212.00 to $216.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 14th. Roth Mkm restated a "buy" rating and set a $212.00 price objective on shares of Insmed in a research report on Friday, April 17th. Raymond James Financial initiated coverage on shares of Insmed in a research report on Friday, April 10th. They set an "outperform" rating and a $200.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Insmed in a research report on Tuesday. Finally, Wells Fargo & Company cut their price objective on shares of Insmed from $208.00 to $175.00 and set an "overweight" rating for the company in a research report on Monday, March 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $213.23.

Insider Activity

In other Insmed news, CEO William Lewis sold 10,699 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares in the company, valued at $43,361,604.45. The trade was a 3.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 88,060 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the transaction, the chief operating officer owned 106,810 shares of the company's stock, valued at approximately $17,584,130.30. This represents a 45.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 179,777 shares of company stock worth $28,252,720. Corporate insiders own 2.10% of the company's stock.

Insmed Trading Down 0.4%

Shares of INSM stock opened at $143.83 on Friday. The firm has a 50 day moving average price of $149.54 and a two-hundred day moving average price of $167.10. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $31.05 billion, a PE ratio of -22.44 and a beta of 1.10. Insmed, Inc. has a 12-month low of $63.81 and a 12-month high of $212.75.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. The firm's quarterly revenue was up 152.6% on a year-over-year basis. As a group, analysts predict that Insmed, Inc. will post -2.51 earnings per share for the current year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.